LifeSignals receives CE Mark Approval for LifeSignals LX1550E Multiparameter Remote Monitoring Platform

LifeSignals Inc., today announced the CE (Conformité Européene) Mark for the LifeSignals LX1550E Multiparameter Remote Monitoring Platform – which can be used by clinicians for the continuous collection of physiological data of patients at home and in healthcare settings.

The single-use, wearable medical biosensor, records Electrocardiography (2-channel ECG), Heart Rate, Respiration rate, Skin Temperature and Body Posture data for up to five days. The encrypted physiological data can then be transmitted with high reliability from the LifeSignals Biosensor, via the Relay App to a secure cloud-based platform. Clinicians and Care Providers can access the cloud-based LifeSignals Remote Monitoring Dashboard to view patient physiological data and manage vital sign alert settings.

The LifeSignals Remote Monitoring Platform is designed to enable healthtech companies to rapidly enhance their product and service portfolios to provide vital sign monitoring to the widest possible patient base, from any location. The interoperable platform can be tailored with ready-to-deploy software development kit APIs and is suitable for large scale implementation.

“COVID-19 has accelerated the adoption of remote patient monitoring globally,” says Steve Jones, Business Development Director, Europe. “This regulatory approval for our Multiparameter Platform is a significant breakthrough and will enable our Partners to bring to market affordable and scalable remote monitoring products and solutions”.

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution